Nebenwirkungen · Degevma
Degevma 120 mg solution for injection · Abschnitt 4.8 · PDF-Seite 9
HOS-152310 · Präparat HOS-100725
A non-randomised, retrospective, observational study in 2,877 patients with cancer treated with denosumab or zoledronic acid in Sweden, Denmark, and Norway showed that 5-year incidence proportions of medically confirmed ONJ were 5.7% (95% CI: 4.4, 7.3; median follow up time of 20 months [range 0.2-60]) in a cohort of patients receiving denosumab and 1.4% (95% CI: 0.8, 2.3; median follow up time of 13 months [range 0.1-60]) in a separate cohort of patients receiving zoledronic acid. Five-year incidence proportion of ONJ in patients switching from zoledronic acid to denosumab was 6.6% (95% CI: 4.2, 10.0; median follow up time of 13 months [range 0.2-60]).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-24T11:32:00Z · SHA-256 42d5e2a42bc26ec6cfe17bc16a0b6c7aefac65193465706eb459c472cc75aee0 · Passage 058b54465327674d76c61560b34532b84c9a8014e0975f9dbe87aa3f63e7af0f · Zeichen 7918–8579 im Abschnitt